ClinConnect ClinConnect Logo
Search / Trial NCT00717509

Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia

Launched by SEOUL NATIONAL HOSPITAL · Jul 16, 2008

Trial Information

Current as of May 01, 2025

Unknown status

Keywords

Schizophrenia Metabolic Side Effect Clozapine Genetic Polymorphism

ClinConnect Summary

The use of antipsychotics, especially clozapine and olanzapine is associated with metabolic side effects, which put patients with schizophrenia at risk for cardiovascular morbidity or diabetes.

The prevalence of the metabolic syndrome was 53.8% of patients who taking clozapine. The high interindividual variability in antipsychotic-induced metabolic abnormalities suggests that genetic makeup is a possible determinant.

The genotypes of the multiple gene such as HTR2C, LEP, adrenergic receptor,PPAR,GNB3 are suggested to have associations with the metabolic side effects (weight,glucose,lipid,...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • age 18-65
  • who can understand and sign the informed consent
  • Exclusion Criteria:
  • who refuse to participate this study

About Seoul National Hospital

Seoul National Hospital, a premier medical institution in South Korea, is dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to excellence in patient care, the hospital leverages its state-of-the-art facilities and a multidisciplinary team of experts to conduct comprehensive clinical studies across various medical fields. As a leader in medical research, Seoul National Hospital aims to enhance therapeutic options and improve patient outcomes while adhering to the highest ethical standards and regulatory compliance. Through collaboration with academic institutions and industry partners, the hospital fosters a culture of discovery and innovation in the pursuit of cutting-edge medical solutions.

Locations

Seoul, , Korea, Republic Of

Patients applied

0 patients applied

Trial Officials

Shi Hyun Kang, M.D.

Study Director

Seoul National Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials